Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CBAYNASDAQ:ITCINASDAQ:SMMTNASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAYCymaBay Therapeutics$32.48$32.44$7.26▼$32.50$3.73B0.324.11 million shs73 shsITCIIntra-Cellular Therapies$131.87$129.53$64.09▼$131.98$14.05B0.691.47 million shsN/ASMMTSummit Therapeutics$18.91-7.6%$20.28$2.10▼$33.89$13.95B-1.043.43 million shs3.45 million shsUTHRUnited Therapeutics$307.36-1.6%$335.35$229.72▼$417.82$13.80B0.64448,589 shs431,930 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAYCymaBay Therapeutics0.00%0.00%0.00%0.00%0.00%ITCIIntra-Cellular Therapies-0.03%+0.09%+0.48%+57.51%+95.89%SMMTSummit Therapeutics-7.58%-8.20%-0.94%+3.67%+378.73%UTHRUnited Therapeutics-1.57%-0.21%-0.40%-13.74%+32.94%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AITCIIntra-Cellular Therapies3.5387 of 5 stars2.23.00.04.53.41.70.6SMMTSummit Therapeutics2.7277 of 5 stars4.52.00.00.02.61.70.0UTHRUnited Therapeutics4.8823 of 5 stars3.34.00.04.63.13.33.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAYCymaBay Therapeutics 0.00N/AN/AN/AITCIIntra-Cellular Therapies 2.33Hold$106.23-19.44% DownsideSMMTSummit Therapeutics 3.00Buy$35.4487.44% UpsideUTHRUnited Therapeutics 2.67Moderate Buy$388.2526.32% UpsideCurrent Analyst Ratings BreakdownLatest CBAY, SMMT, ITCI, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025ITCIIntra-Cellular TherapiesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$132.00 ➝ $132.003/26/2025SMMTSummit TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$23.00 ➝ $35.003/21/2025SMMTSummit TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight3/12/2025SMMTSummit TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$30.002/28/2025SMMTSummit TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$42.002/27/2025UTHRUnited TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$425.00 ➝ $425.002/25/2025SMMTSummit TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$44.00 ➝ $44.002/24/2025ITCIIntra-Cellular TherapiesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$140.00 ➝ $132.002/21/2025ITCIIntra-Cellular TherapiesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold1/31/2025ITCIIntra-Cellular TherapiesCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$119.00 ➝ $132.001/22/2025ITCIIntra-Cellular TherapiesRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Sector Perform$108.00 ➝ $132.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59ITCIIntra-Cellular Therapies$680.50M20.64N/AN/A$6.15 per share21.44SMMTSummit Therapeutics$700K19,927.90N/AN/A$0.11 per share171.91UTHRUnited Therapeutics$2.88B4.80$18.48 per share16.63$127.35 per share2.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%N/AITCIIntra-Cellular Therapies-$139.67M-$0.73N/A694.05N/A-14.07%-9.93%-8.38%5/6/2025 (Estimated)SMMTSummit Therapeutics-$614.93M-$0.31N/AN/AN/AN/A-85.42%-52.66%4/29/2025 (Estimated)UTHRUnited Therapeutics$984.80M$24.6013.5011.180.9740.31%19.22%16.15%4/29/2025 (Estimated)Latest CBAY, SMMT, ITCI, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/29/2025N/ASMMTSummit Therapeutics-$0.0715N/AN/AN/AN/AN/A2/26/2025Q4 24UTHRUnited Therapeutics$6.10$6.19+$0.09$6.19$734.74 million$735.90 million2/24/2025Q4 2024SMMTSummit Therapeutics-$0.08-$0.08N/A-$0.08N/A$0.20 million2/21/2025Q4 2024ITCIIntra-Cellular Therapies-$0.08-$0.16-$0.08-$0.16$205.08 million$199.22 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AITCIIntra-Cellular TherapiesN/AN/AN/AN/AN/ASMMTSummit TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAYCymaBay TherapeuticsN/A10.9610.96ITCIIntra-Cellular TherapiesN/A7.667.51SMMTSummit TherapeuticsN/A8.318.31UTHRUnited TherapeuticsN/A4.584.41Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAYCymaBay Therapeutics95.03%ITCIIntra-Cellular Therapies92.33%SMMTSummit Therapeutics4.61%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipCBAYCymaBay Therapeutics7.00%ITCIIntra-Cellular Therapies2.60%SMMTSummit Therapeutics88.30%UTHRUnited Therapeutics11.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableITCIIntra-Cellular Therapies560106.52 million103.56 millionOptionableSMMTSummit Therapeutics110737.68 million86.28 millionOptionableUTHRUnited Therapeutics98044.91 million39.33 millionOptionableCBAY, SMMT, ITCI, and UTHR HeadlinesRecent News About These CompaniesHeadlands Technologies LLC Sells 1,464 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 4 at 5:08 AM | marketbeat.comFranklin Resources Inc. Increases Stake in United Therapeutics Co. (NASDAQ:UTHR)April 4 at 4:50 AM | marketbeat.comAllstate Corp Acquires Shares of 1,176 United Therapeutics Co. (NASDAQ:UTHR)April 4 at 4:12 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by American Century Companies Inc.April 3 at 3:33 AM | marketbeat.comUnited Therapeutics Named to ‘100 Best Companies to Work For’ in 2025 by Fortune Media and Great Place to WorkApril 2 at 11:36 PM | finance.yahoo.comUnited Therapeutics Corp (UTHR) Recognized as a Top Employer by FortuneApril 2 at 1:41 PM | gurufocus.comIs United Therapeutics Corporation (UTHR) The Most Profitable Biotech Stock To Buy Right Now?April 2 at 10:30 AM | insidermonkey.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Alliancebernstein L.P.April 2 at 5:33 AM | marketbeat.comAxiom Investors LLC DE Increases Position in United Therapeutics Co. (NASDAQ:UTHR)April 2 at 5:25 AM | marketbeat.comWellington Management Group LLP Reduces Holdings in United Therapeutics Co. (NASDAQ:UTHR)April 2 at 5:15 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Brandywine Global Investment Management LLCApril 2 at 5:07 AM | marketbeat.comCalifornia Public Employees Retirement System Lowers Holdings in United Therapeutics Co. (NASDAQ:UTHR)April 2 at 4:57 AM | marketbeat.comSchroder Investment Management Group Lowers Stake in United Therapeutics Co. (NASDAQ:UTHR)April 2 at 4:49 AM | marketbeat.comNomura Asset Management Co. Ltd. Has $8.69 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)April 2 at 4:24 AM | marketbeat.comNorges Bank Takes Position in United Therapeutics Co. (NASDAQ:UTHR)April 2 at 4:22 AM | marketbeat.comUniSuper Management Pty Ltd Sells 13,826 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 2 at 4:15 AM | marketbeat.comMitsubishi UFJ Asset Management Co. Ltd. Purchases 3,312 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 2 at 4:07 AM | marketbeat.comNotable Monday Option Activity: UTHR, TEAM, UNHApril 2 at 3:41 AM | nasdaq.comArrowstreet Capital Limited Partnership Sells 99,154 Shares of United Therapeutics Co. (NASDAQ:UTHR)April 1 at 5:09 AM | marketbeat.comUnited Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Pictet Asset Management Holding SAApril 1 at 4:32 AM | marketbeat.com4,637 Shares in United Therapeutics Co. (NASDAQ:UTHR) Purchased by New Age Alpha Advisors LLCApril 1 at 4:31 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCBAY, SMMT, ITCI, and UTHR Company DescriptionsCymaBay Therapeutics NASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.Intra-Cellular Therapies NASDAQ:ITCI$131.87 0.00 (0.00%) As of 04/2/2025Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Summit Therapeutics NASDAQ:SMMT$18.91 -1.55 (-7.58%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$17.85 -1.06 (-5.60%) As of 07:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.United Therapeutics NASDAQ:UTHR$307.36 -4.90 (-1.57%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$301.92 -5.44 (-1.77%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
